However, both sporadic AD and ADAD share core neuropathological features and biomarker abnormalities including amyloid and tau accumulation, FDG-PET hypometabolism, and neurodegeneration.28,41 Importantly, the emergence of cognitive symptoms in ADAD is driven by AD pathology rather than age-related comorbidities, and thus, provides a good model for AD-related cognitive decline.27,42. The gene discussed is MAPT; the disease is Alzheimer disease.